Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment

Psychological Medicine

Volumn 42, Issue 7, 2012, Pages 1475-1483

  Li, M ^a   Chen, Z ^a   Deng, W ^a   He, Z ^a   Wang, Q ^a   Jiang, L ^a   Ma, X ^a   Wang, Y ^a   Chua, S E ^b   Cheung, C ^b   McAlonan, G M ^b   Sham, P C ^b   Collier, D A ^c   Gong, Q ^a   Li, T ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; longitudinal; MRI scan; putamen; schizophrenia

Indexed keywords

BIOLOGICAL MARKER; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHINA; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FOLLOW UP; HEMISPHERIC DOMINANCE; HUMAN; IMAGE PROCESSING; MALE; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PUTAMEN; SCHIZOPHRENIA; STATISTICS; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHINA; FEMALE; FOLLOW-UP STUDIES; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PUTAMEN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861418968     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291711002157     Document Type: Article

References (62)

1. Abi-Dargham A (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology 7, S1-S5. (Pubitemid 38436990)
2. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action-a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228-1235. (Pubitemid 37494076)
3. Annett M (1970). A classification of hand preference by association analysis. British Journal of Psychiatry 61, 303-321.
4. Ashburner J, Friston KJ (2004). Morphometry. In Human Brain Function (ed. R. S. J. Frackowiak). Academic Press, Elsevier Science: California, USA.
5. Atkins M, Burgess A, Bottomley C, Riccio M (1997). Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatric Bulletin 21, 224-226. (Pubitemid 27225823)
6. Backman L, Ginovart N, Dixon RA, Wahlin TBR, Wahlin A, Halldin C, Farde L (2000). Age-related cognitive deficits mediated by changes in the striatal dopamine system. American Journal of Psychiatry 157, 635-637. (Pubitemid 30191207)
7. Beckmann H, Lauer M (1997). The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiatry Research Neuroimaging 68, 99-109. (Pubitemid 27191433)
8. Beng-Choon H, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Archives of General Psychiatry 68, 128-137.
9. Boonstra G, van Haren N, Schnack HG, Cahn W, Burger H, Boersma M, de Kroon B, Grobbee DE, Hulshoff Pol HE, Kahn RS (2011). Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. Journal of Clinical Psychopharmacology 31, 146-153.
10. Borta A, Hoglinger GU (2007). Dopamine and adult neurogenesis. Journal of Neurochemistry 100, 587-595. (Pubitemid 46095611)
11. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu HW, Kinon B, Ashtari M (1994). Increase in caudate nuclei volumes of first-episode schizophrenia-patients taking antipsychotic-drugs. American Journal of Psychiatry 151, 1430-1436. (Pubitemid 24301686)
12. Chua SE, Cheung C, Cheung V, Tsang JTK, Chen EYH, Wong JCH, Cheung JPY, Yip L, Tai KS, Suckling J, McAlonan GM (2007). Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophrenia Research 89, 12-21. (Pubitemid 44895585)
13. Chua SE, Deng Y, Chen EYH, Law CW, Chiu CPY, Cheung C, McAlonan GM (2009). Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychological Medicine 39, 793-800.
14. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM (2005). Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 30, 765-774. (Pubitemid 40397083)
15. Deng MY, McAlonan GM, Cheung C, Chiu CPY, Law CW, Cheung V, Sham PC, Chen EYH, Chua SE (2009). A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naive, newly diagnosed schizophrenia. Psychopharmacology 206, 437-446.
16. Emsley R, Rabinowitz J, Medori R (2006). Time course for antipsychotic treatment response in first-episode schizophrenia. American Journal of Psychiatry 163, 743-745. (Pubitemid 44464590)
17. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2005). World Federation of Societies of Biological Psychiatry (WFSBP)-guidelines for biological treatment of schizophrenia. Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 6, 132-191.
18. First MB, Spitzer RL, Gibbon M, Williams JB (1996). Structured Clinical Interview for DSM-IV Axis I Disorders-Non-Patient Edition (SCID-I/NP), version 2.0. New York State Psychiatric Institute, Biometrics Research: New York.
19. Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, Baare WFC (2007). Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Research: Neuroimaging 154, 199-208. (Pubitemid 46428524)
20. Gunduz H, Wu HW, Ashtari M, Bogerts B, Crandall D, Robinson DG, Alvir J, Lieberman J, Kane J, Bilder R (2002). Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biological Psychiatry 51, 801-808. (Pubitemid 34451067)
21. Gur RE, Maany V, Mozley D, Swanson C, Bilker W, Gur RC (1998). Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. American Journal of Psychiatry 155, 1711-1717. (Pubitemid 28547495)
22. Harris MSH, Reilly JL, Keshavan MS, Sweeney JA (2006). Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychological Medicine 36, 485-494. (Pubitemid 43381001)
23. Heinz A, Schlagenhauf F (2010). Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophrenia Bulletin 36, 472-485.
24. Honea R, Crow TJ, Passingham D, Mackay CE (2005). Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 162, 2233-2245. (Pubitemid 41740200)
25. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: version III-025EF. The final common pathway. Schizophrenia Bulletin 35, 549-562.
26. Huang XQ, Lui S, Deng W, Chan RCK, Wu QZ, Jiang LJ, Zhang JR, Jia ZY, Li F, Li XL, Chen L, Li T, Gong QY (2009). Localization of cerebral functional deficits in treatment-naive, first-episode schizophrenia using restingstate fMRI. NeuroImage 49, 2901-2906.
27. Ifthikharuddin SF, Shrier DA, Numaguchi Y, Tang X, Ning R, Shibata DK, Kurlan R (2000). MR volumetric analysis of the human basal ganglia: normative data. Academic Radiology 7, 627-634. (Pubitemid 30602831)
28. Jayakumar PN, Venkatasubramanian G, Gangadhar BN, Janakiramaiah N, Keshavan MS (2005). Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29, 587-591. (Pubitemid 40603835)
29. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225. (Pubitemid 29067401)
30. Kawasaki Y, Suzuki M, Takahashi T, Nohara S, McGuire PK, Seto H, Kurachi M (2008). Anomalous cerebral asymmetry in patients with schizophrenia demonstrated by voxel-based morphometry. Biological Psychiatry 63, 793-800. (Pubitemid 351400761)
31. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276. (Pubitemid 18039085)
32. Keilhoff G, Grecksch G, Bernstein HG, Roskoden T, Becker A (2010). Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. European Archives of Psychiatry & Clinical Neuroscience 260, 151-162.
33. Kippin TE, Kapur S, van der Kooy D (2005). Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. Journal of Neuroscience 25, 5815-5823. (Pubitemid 40847894)
34. Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biological Psychiatry 50, 729-742. (Pubitemid 33086760)
35. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL (2009). Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology 34, 2675-2690.
36. Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, Honer WG (2001). An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. American Journal of Psychiatry 158, 625-631. (Pubitemid 32289827)
37. Larisch R, Meyer W, Klimke A, Kehren F, Vosberg H, Muller-Gartner HW (1998). Left-right asymmetry of striatal dopamine D2 receptors. Nuclear Medicine Communication 19, 781-787. (Pubitemid 28407510)
38. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, Twemlow SW, Woods S, Yager J, Gray SH, Askland K, Pandya R, Prasad K, Johnston R, Nininger J, Peele R, Anzia DJ, Benson RS, Lurie L, Walker RD, Kunkle R, Simpson A, Fochtmann LJ, Hart C, Regier D (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161, 1-56.
39. Leow AD, Klunder AD, Jack CR, Toga AW, Dale AM, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Whitwell JL, Borowski BJ, Fleisher AS, Fox NC, Harvey D, Kornak J, Schuff N, Studholme C, Alexander GE, Weiner MW, Thompson PM (2006). Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. NeuroImage 31, 627-640. (Pubitemid 44218807)
40. Leucht S., Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57, 1543-1549. (Pubitemid 40805384)
41. Lui S, Deng W, Huang XQ, Jiang LJ, Ma XH, Chen HF, Zhang TJ, Li XL, Li DM, Zou L, Tang HH, Zhou XHJ, Mechelli A, Collier DA, Sweeney JA, Li T, Gong QY (2009). Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. American Journal of Psychiatry 166, 196-205.
42. Massana G, Salgado-Pineda P, Junque C, Perez M, Baeza I, Pons A, Massana J, Navarro V, Blanch J, Morer A, Mercader JM, BernardoM(2005). Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. Journal of Clinical Psychopharmacology 25, 111-117. (Pubitemid 40395088)
43. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 101, 323-329. (Pubitemid 30173584)
44. Navari S, Dazzan P (2009). Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 39, 1763-1777.
45. Okugawa G, Nobuhara K, Takase K, Saito Y, Yoshimura M, Kinoshita T (2007). Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia. Neuropsychobiology 55, 43-46. (Pubitemid 47000397)
46. Premkumar P, Kumari V, Corr PJJ, Sharma T (2006). Frontal lobe volumes in schizophrenia: effects of stage and duration of illness. Journal of Psychiatric Research 40, 627-637. (Pubitemid 44333115)
47. Reeves SJ, Grasby PM, Howard RJ, Bantick RA, Asselin MC, Mehta MA (2005). A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition. NeuroImage 28, 216-226. (Pubitemid 41393901)
48. Schultz W (2007). Behavioral dopamine signals. Trends in Neurosciences 30, 203-210. (Pubitemid 46654238)
49. Seeman P, Kapur S (2000). Schizophrenia: more dopamine, more D2 receptors. Proceedings of the National Academy of Sciences USA 97, 7673-7675.
50. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001). A review of MRI findings in schizophrenia. Schizophrenia Research 49, 1-52. (Pubitemid 32451739)
51. Shihabuddin L, Buchsbaum MS, Hazlett EA, Haznedar MM, Harvey PD, Newman A, Schnur DB, Spiegel-Cohen J, Wei TS, Machac J, Knesaurek K, Vallabhajosula S, Biren MA, Ciaravolo TM, Luu-Hsia C (1998). Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Archives of General Psychiatry 55, 235-243.
52. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rossler A, Borgwardt SJ (2009). The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?-A systematic review. Current Pharmaceutical Design 15, 2535-2549.
53. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA (2006). Brain volume in first-episode schizophrenia-systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry 188, 510-518. (Pubitemid 43844097)
54. Takao H, Abe O, Yamasue H, Aoki S, Kasai K, Ohtomo K (2010). Cerebral asymmetry in patients with schizophrenia: a voxel-based morphometry (VBM) and diffusion tensor imaging (DTI) study. Journal of Magnetic Resonance Imagine 31, 221-226.
55. Taylor S, Christensen JD, Holcomb JM, Garver DL (2005). Volume increases in striatum associated with positive symptom reduction in schizophrenia: a preliminary observation. Psychiatry Research Neuroimaging 140, 85-89. (Pubitemid 41443499)
56. Toda M, Abi-Dargham A (2007). Dopamine hypothesis of schizophrenia: making sense of it all. Current Psychiatry Reports 9, 329-336. (Pubitemid 47490006)
57. Tomelleri L, Jogia J, Perlini C, Bellani M, Ferro A, Rambaldelli G, Tansella M, Frangou S, Brambilla P (2009). Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 19, 835-840.
58. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J (1998). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. American Journal of Psychiatry 155, 344-349. (Pubitemid 28114890)
59. Wang HD, Dunnavant FD, Jarman T, Deutch AY (2004). Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29, 1230-1238. (Pubitemid 38780646)
60. Watkins KE, Paus T, Lerch JP, Zijdenbos A, Collins DL, Neelin P, Taylor J, Worsley KJ, Evans AC (2001). Structural asymmetries in the human brain: a voxel-based statistical analysis of 142 MRI scans. Cerebral Cortex 11, 868-877. (Pubitemid 32800553)
61. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667. (Pubitemid 36750143)
62. Yamashita K, Yoshiura T, Hiwatashi A, Noguchi T, Togao O, Takayama Y, Nagao E, Kamano H, Hatakenaka M, Honda H (2011). Volumetric asymmetry and differential aging effect of the human caudate nucleus in normal individuals: a prospective MR imaging study. Journal of Neuroimaging 21, 34-37.